The original disclosure in Japanese was released on July 29, 2014 at 15:30 (GMT+9)

Consolidated Financial Statements for the First Quarter Ended June 30, 2014
FY2015 (April 1, 2014 - March 31, 2015) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: http://www.takara.co.jp/
Company representative: Toshio Kakimoto, President
Contact: Takuya Kakemi, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124

Quarterly statement filing date (as planned): August 8, 2014

Notes:
1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2014 (April 1, 2014 - June 30, 2014)

(1) Operating results

Note: Percentages indicated changes from the previous fiscal year.

	Three months ended June 30, 2014		Three months ended June 30, 2013	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	50,025	6.5	46,953	(0.8)
Operating income (loss)	1,182	-	(241)	-
Ordinary income	1,486	-	20	(98.2)
Net income (loss)	811	-	(86)	-
Net income (loss) per share (Yen)	4.03		(0.43)	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income	149	(93.7)	2,364	120.5

(2) Financial position

	As of June 30, 2014	As of March 31, 2014
	(Millions of yen)	(Millions of yen)
Total assets	233,915	238,577
Net assets	144,714	146,422
Equity ratio (%)	51.3	50.9
(Reference) Equity	119,989	121,431

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2014	Year ending March 31, 2015	Year ending March 31, 2015 (Forecast)
First quarter end	-	-	
Second quarter end	-		-
Third quarter end	-		-
Year end	11.00		9.00
Annual	11.00		9.00

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2015 (April 1, 2014 - March 31, 2015)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2014		Year ending March 31, 2015	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	101,000	3.5	218,000	4.0
Operating income	2,570	7.3	9,800	3.3
Ordinary income	2,570	0.2	10,000	0.9
Net income	1,250	(81.1)	5,300	(48.4)
Net income per share (Yen)	6.21		26.34	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change is subsidiaries) : No

(2) Applying of specific accounting of the consolidated quarterly financial statements : No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard : Yes

2) Changes other than ones based on revisions of accounting standard : Yes

3) Changes in accounting estimates : Yes

4) Restatement : No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of June 30, 2014 : 217,699,743

As of March 31, 2014 : 217,699,743

2) Number of treasury stocks at year end

As of June 30, 2014 : 16,473,135

As of March 31, 2014 : 16,466,424

3) Average number of outstanding shares

Three months ended June 30, 2014 : 201,230,699

Three months ended June 30, 2013 : 202,862,913

Contents of the attached document

1. Qualitative Information for the Three Months Ended June 30, 2014 ---------- 2
   (1) Consolidated Financial Results ---------- 2
   (2) Consolidated Financial Position ---------- 3
   (3) Qualitative Information Regarding Consolidated Forecasts ---------- 3
2. Summary Information (Notes)---------- 4
   Change in Accounting Policies and Changes and Retrospective Restatement of Accounting Estimates---- 4
3. Consolidated Quarterly Financial Statements ---------- 5
   (1) Consolidated Quarterly Balance Sheets ---------- 5
   (2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2013 and 2012) ---------- 7
   Consolidated Quarterly Statements of Income (For the Three Months Ended June 30, 2013 and 2012) --- 7
   Consolidated Quarterly Statements of Comprehensive Income (For the Three Months Ended June 30, 2013 and 2012) ---------- 8
   (3) Notes on Consolidated Quarterly Financial Statements ---------- 9
   (Notes on Premise of Going Concern) ---------- 9
   (Notes on Material Changes in Shareholders' Equity) ---------- 9
   (Segment Information) ---------- 9

○ Supplement for the Consolidated Quarterly Financial Statements

1. Qualitative Information for the Three Months Ended June 30, 2013

(1) Consolidated Financial Results

In the three months ended June 30, 2014, the Japanese economy experienced a moderate recovery as the reaction to the last-minute demand accompanying the increase in the rate of the consumption tax gradually eased off.

In this environment, we endeavored to further improve corporate value in accordance with the three-year Takara Group Medium-Term Management Plan FY2017 under which our basic policy is that "To achieve the Takara Group Vision 2020 (our long-term vision), we will improve domestic business profitability and expand our overseas business, while at the same time building a well-balanced business structure that can hold up well to business environment changes by accelerating the growth of our Biomedical business."

In the domestic alcoholic beverages business, the Group focused its resources on developing original new products and cultivating brands in response to diversifying customer preferences. In the seasonings and raw alcohol business, the Group made concerted efforts to increase sales by proposing differentiated products that meet customer needs.

In the overseas alcoholic beverages business and Japanese food wholesales business in overseas markets, the Group worked to accelerate business expansion by spreading Japanese food culture across the globe

In the Biomedical business, management resources were focused on three areas – the Genetic engineering research business, the Gene therapy business, and the AgriBio business – in pursuit of improved performance.

In the three months ended June 30, 2014, net sales were up 6.5% year on year to ¥50,025 million due to the inclusion of sales from subsidiaries that were newly consolidated during the previous fiscal year and an increase in sales at overseas subsidiaries due to the depreciation in the value of the yen. Gross profit also rose 9.3% year on year to ¥18,994 million in tandem with the increase in net sales.

Selling, general and administrative (SG&A) expenses were up 1.1% year on year to ¥17,811 million. Consequently, operating income improved considerably to ¥1,182 million from an operating loss of ¥241 million recorded in the three months ended June 30, 2013. In regard to non-operating income and expenses, dividends income and equity in earnings of affiliates increased. Thus, ordinary income also rose dramatically to ¥1,486 million from ¥20 million recorded in the three months ended June 2013.

In regard to extraordinary income and loss, despite recording loss on sale and retirement of noncurrent assets, income before income taxes and minority interests increased considerably year on year to ¥1,411 million, and net income of ¥811 million was recorded compared with a net loss of ¥86 million recorded in the three months ended June 2013.

Results by business segment were as follows.

[Takara Shuzo Group]

In the three months ended June 2014, overall sales of alcoholic beverages rose slightly as sales of light-alcoholic refreshers were lower while sales of sparkling sake higher driven by strong sales of sparkling sake *Sho-Chiku-Bai Shirakabe-gura Mio*. For seasonings, in addition to a decline in sales of mirin in a reaction to last-minute demand in advance of the increase in the rate of consumption tax, sales of products such as raw alcohol and distribution also declined.

Meanwhile, total net sales for the Takara Shuzo Group increased 5.7% year on year to ¥44,370 million because sales in the Japanese food wholesale business in overseas markets rose substantially with the inclusion of sales at TAZAKI FOODS LTD. (UK) and COMINPORT DISTORIBUCIÓN S.L. (Spain), which were consolidated during the previous fiscal year.

Cost of sales was up 5.1% year on year to ¥28,623 million accompanying the increase in net sales. Gross profit was also up 6.9% to ¥15,746 million. SG&A expenses only increased 0.3% year on year to ¥14,916 million because advertising expenses fell despite increases in personnel expenses and management expenses. Accordingly, the Takara Shuzo Group recorded operating income of ¥830 million compared with an operating loss of ¥134 million recorded in the three months ended June 2013.

[Takara Bio Group]

Net sales increased 14.6% to ¥4,779 million as sales of the mainstay research reagents exceeded those of the same quarter of the previous fiscal year, due in part to the effect of the depreciation in the value of the yen. Cost of sales was up 2.4% to ¥2,024 million due to a lower cost of sales ratio arising from differences between the cost of sales ratios of individual products. Consequently, gross profit increased 25.6% to ¥2,754 million. Higher personnel expenses and other factors led to an increase of 5.4% in SG&A expenses at ¥2,689 million. However, the Takara Bio Group recorded operating income of ¥65 million compared with an operating loss of ¥358 million recorded in the three months ended June 2013.

[Takara Healthcare]

Net sales increased substantially by 31.6% year on year to ¥385 million due to strong sales of its mainstay fucoidan-related products and isosamidin-related products. Gross profit increased in conjunction with sales, and, as SG&A expenses declined year on year, Takara Healthcare recorded an operating profit of ¥9 million compared with an operating loss of ¥39 million recorded in the three months ended June 2013.

[Other]

Net sales of business segments other than the reported segments decreased 4.1% year on year, to ¥1,594 million, and operating income was down 77.7%, to ¥6 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2013, to June 30, 2013)	Period under Review (from April 1, 2014, to June 30, 2014)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo Group			
Shochu	16,484	16,609	100.8
Sake	3,910	4,238	108.4
Light-alcohol refreshers	6,903	6,403	92.8
Other alcoholic beverages	2,962	3,239	109.4
Alcoholic beverages total	30,261	30,491	100.8
Hon Mirin	3,330	3,097	93.0
Other seasonings	1,952	2,014	103.2
Seasonings total	5,282	5,111	96.8
Raw alcohol, etc.	1,670	1,588	95.1
Transportation	2,811	2,731	97.1
Japanese food wholesales business in overseas markets	1,544	4,032	261.0
Other	407	415	101.8
Total	41,978	44,370	105.7
Takara Bio Group	4,170	4,779	114.6
Takara Healthcare	292	385	131.6
Other	1,663	1,594	95.9
Sales not allocated to business segments and intersegment transactions	(1,151)	(1,104)	-
Total	**46,953**	**50,025**	**106.5**

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

Total assets stood at ¥233,915 million as of June 30, 2014, down ¥4,661 million from March 31, 2014, the end of the previous fiscal year. This was due to a ¥6,298 million decline in current assets due to such factors as a decrease in securities for the management of surplus funds, which offset a ¥1,637 million increase in total noncurrent assets as a result of a rise in investment securities due to an increase in the market prices of listed stocks and other items. The decrease in securities was primarily the result of expenditure for the payment of income taxes.

Total liabilities amounted to ¥89,201 million as of June 30, 2014, down ¥2,953 million from March 31, 2014, because of the decrease of ¥4,838 million in total non-current liabilities outweighed the ¥1,884 million increase in total current liabilities that was the result of factors including the transfer of current portion of bonds and decrease in income taxes payable.

Total net assets were ¥144,714 million as of June 30, 2014, down ¥1,708 million from March 31, 2014 mainly due to a decrease in retained earnings because of dividend payments.

(3) Qualitative Information Regarding Consolidated Forecasts

In the three months ended June 30, 2014, net sales and operating income slightly exceeded initial forecasts. Nevertheless, the Company has not revised the consolidated forecasts for the six months ending September 30, 2014 or for the fiscal year ending March 31, 2015 that were released on May 8, 2014 because the proportion of the Group's annual income accounted for by income in the first quarter of the fiscal year is relatively low, the fact that future trends in consumption and exchange rates are uncertain, and other factors.

2. Summary Information (Notes)

Change in Accounting Policy and Retrospective Restatement of Accounting Estimates

(Change in Accounting Policy)

(Application of Accounting Standard for Retirement Benefits)

The Company adopted the provisions in the main text of paragraph 35 of the Accounting Standard for Retirement Benefits (Accounting Standards Board of Japan ("ASBJ") Statement No. 26, May 17, 2012) and the main text of paragraph 67 of the Application Guidance on Accounting Standard for Retirement Benefits (ASBJ Guidance No. 25, May 17, 2012) from the first quarter of this fiscal year, revising the method of calculating retirement benefit obligations and service expenses, modifying the method of attributing expected benefit to periods from the straight-line basis to the benefit formula basis as well as changing the discount rate from one based on the average remaining service years of its employees to a single weighted average discount rate reflecting the expected timing and amount of benefit payments.

In accordance with the transitional measures provided for in paragraph 37 of the Accounting Standard for Retirement Benefits for the application of the Accounting Standard for Retirement Benefits and its Guidance, the effect of the change in the method of calculation of retirement benefit obligations and service costs has been added to or deducted from retained earnings as of the beginning of first quarter of this fiscal year (the quarter ended June 30, 2014).

As a result, at the beginning of the first quarter of this fiscal year, net defined benefit liabilities fell ¥313 million while other in investments and other assets increased by ¥359 million, retained earnings increased by ¥414 million and minority interests increased by ¥16 million. The impact on consolidated operating income, ordinary income and net income before taxes in the three months ended June 30, 2014 was immaterial.

(Change in Accounting Policy that is Difficult to Distinguish from Change in Accounting Estimates)

(Change in Method of Depreciation for Property, Plant and Equipment)

Consolidated subsidiary Takara Bio Inc. previously applied declining balance depreciation to property, plant and equipment but switched to straight-line depreciation from the three months ended June 30, 2014.

Takara Bio reconsidered its method of depreciation and determined that this change from declining balance to straight-line depreciation is reasonable in view of the fact that the stable utilization of property, plant and equipment in research and development and production activities is anticipated because it has been 12 years since the company was established and facilities that include the Center for Gene and Cell Processing will be in operation from this fiscal year.

The impact of this change on consolidated operating income, ordinary income and net income before taxes in the three months ended June 30, 2014 is an increase of ¥15 million respectively.

3. Consolidated Quarterly Financial Statements

(1) Consolidated Quarterly Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2014	As of Jun. 30, 2014
Assets		
Current assets		
Cash and deposits	41,015	38,381
Notes and accounts receivable-trade	51,901	50,392
Securities	21,534	18,013
Merchandise and finished goods	26,729	27,331
Work in process	908	1,039
Raw materials and supplies	3,351	3,210
Other	5,254	6,034
Allowance for doubtful accounts	(143)	(150)
Total current assets	150,551	144,252
Noncurrent assets		
Property, plant and equipment	47,976	48,727
Intangible assets		
Goodwill	7,539	7,260
Other	4,123	4,076
Total intangible assets	11,662	11,336
Investments and other assets		
Investment securities	23,532	24,600
Other	5,077	5,231
Allowance for doubtful accounts	(223)	(232)
Total investments and other assets	28,386	29,599
Total noncurrent assets	88,025	89,662
Total assets	238,577	233,915
Liabilities		
Current liabilities		
Notes and accounts payable-trade	14,416	14,209
Short-term loans payable	5,914	5,801
Current portion of bonds	-	5,000
Accrued alcohol tax	8,376	7,579
Accrued expenses	4,480	3,763
Income taxes payable	5,621	679
Provision for bonuses	2,081	3,218
Other provision	1,817	1,893
Other	5,953	8,402
Total current liabilities	48,663	50,548
Noncurrent liabilities		
Bonds payable	25,000	20,000
Long-term loans payable	310	301
Net defined benefit liability	6,943	6,663
Long-term deposits received	5,591	5,647
Other	5,644	6,041
Total noncurrent liabilities	43,491	38,653
Total liabilities	92,154	89,201

(Millions of Yen)

	As of Mar. 31, 2014	As of Jun. 30, 2014
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	3,196	3,196
Securities	104,739	103,753
Merchandise and finished goods	(9,931)	(9,936)
Total noncurrent assets	111,230	110,238
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	5,941	6,578
Deferred gains or losses on hedges	279	186
Foreign currency translation adjustment	2,894	1,945
Remeasurements of defined benefit plans	1,085	1,039
Total accumulated other comprehensive income	10,200	9,750
Minority interests	24,991	24,724
Total net assets	146,422	144,714
Total liabilities and net assets	238,577	233,915

(2) Consolidated Quarterly Statements of Income and Consolidated Quarterly Statements of Comprehensive Income

(Consolidated Quarterly Statements of Income)

(For the Three Months Ended June 30, 2014 and 2013) (Millions of Yen)

	FY2014 1Q (Apr. 1, 2013 – Jun. 30, 2013)	FY2015 1Q (Apr. 1, 2014 – Jun. 30, 2014)
Net sales	46,953	50,025
Cost of sales	29,570	31,031
Gross profit	17,382	18,994
Selling, general and administrative expenses	17,624	17,811
Operating income(loss)	(241)	1,182
Non-operating income		
Dividends income	186	221
Share of profit of entities accounted for using equity method	69	102
Other	144	147
Total non-operating income	400	470
Non-operating expenses		
Interest expenses	114	121
Other	23	46
Total non-operating expenses	138	167
Ordinary income	20	1,486
Extraordinary income		
Gain on sales of noncurrent assets	0	4
Gain on change in equity	29	-
Other	2	-
Total extraordinary income	33	4
Extraordinary loss		
Loss on sales and retirement of noncurrent assets	19	37
Directors' retirement benefits	24	34
Other	0	7
Total extraordinary losses	44	79
Income before income taxes and minority interests	9	1,411
Income taxes-current	684	920
Income taxes-deferred	(540)	(395)
Total income taxes	144	524
Net income (loss) before minority interests	(134)	886
Minority interests in income (loss)	(47)	75
Net income (loss)	(86)	811

（Consolidated Quarterly Statements of Comprehensive Income）
(For the Three Months Ended June 30, 2014 and 2013) (Millions of Yen)

	FY2014 1Q (Apr. 1, 2013 – Jun. 30, 2013)	FY2015 1Q (Apr. 1, 2014 – Jun. 30, 2014)
Net income (loss) before minority interests	(134)	886
Other comprehensive income		
Valuation difference on available-for-sale securities	486	637
Deferred gains or losses on hedges	112	(94)
Foreign currency translation adjustment	1,781	(1,181)
Remeasurements of defined benefit plans	-	(46)
Share of other comprehensive income of associates accounted for using equity method	117	(51)
Total other comprehensive income	2,498	(737)
Comprehensive income	2,364	149
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	1,995	361
Comprehensive income attributable to minority interests	368	(212)

(3) Notes on Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2013, to June 30, 2013)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	41,892	4,092	292	46,277	570	46,847	105	46,953
Intersegment	85	77	0	164	1,093	1,257	(1,257)	-
Total	41,978	4,170	292	46,441	1,663	48,104	(1,151)	46,953
Segment income (loss)	(134)	(358)	(39)	(532)	31	(501)	259	(241)

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income (loss) comprises intersegment eliminations of ¥71 million and income of the Company not allocated to business segments of ¥187 million.
3. Segment income (loss) has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2014, to June 30, 2014)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo Group	Takara Bio Group	Takara Healthcare	Subtotal				
Net sales								
External customers	44,287	4,635	385	49,308	605	49,913	111	50,025
Intersegment	82	143	0	226	989	1,216	(1,216)	-
Total	44,370	4,779	385	49,535	1,594	51,129	(1,104)	50,025
Segment income	830	65	9	905	6	912	270	1,182

Notes: 1. Other includes business segments that are not part of reported segments, such as the printing business and other subsidiaries.
2. Details of adjustment amounts are as follows.
(1) Net sales to external customers are income from real estate rent recognized by the Company.
(2) Segment income comprises intersegment eliminations of ¥65 million and income of the Company not allocated to business segments of ¥205 million.
3. Segment income has been adjusted to the operating loss of consolidated quarterly statements of income.

2. Matters concerning Changes to Reporting Segments

(Change in Method of Depreciation for Property, Plant and Equipment)

Consolidated subsidiary Takara Bio Inc. previously applied declining balance depreciation to property, plant and equipment but switched to straight-line depreciation from the three months ended June 30, 2014.

With this change, segment income for the Takara Bio Group for the three months ended June 30, 2014 increased ¥15 million compared with the previous method of depreciation.

3. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

平成27年3月期
第1四半期決算短信 補足資料

Supplement for the Consolidated Financial Statements
for the First Quarter Ended June 30, 2014

1. 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造グループ
   Takara Shuzo Group
   要約損益計算書
   Statements of Income (Summary)

3. タカラバイオグループ
   Takara Bio Group
   要約損益計算書
   Statements of Income (Summary)

4. 6年間の財務サマリー(グループ別)
   Six-Year Financial Summary by Business Group

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc. Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	平成26年3月期 第1四半期	平成27年3月期 第1四半期 Apr. 1, 2014 - Jun. 30, 2014		
	実績(a) FY2014 (1stQ) Actual (a)	実績(b) FY2015 (1stQ) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
宝酒造 グループ Takara Shuzo Group	41,978	44,370	2,391	105.7%
タカラバイオ グループ Takara Bio Group	4,170	4,779	609	114.6%
宝ヘルスケア Takara Healthcare Inc.	292	385	92	131.6%
その他 Other, net	511	490	△ 21	95.8%
売上高 Net sales	46,953	50,025	3,072	106.5%
売上原価 Cost of sales	29,570	31,031	1,461	104.9%
売上総利益 Gross profit	17,382	18,994	1,611	109.3%
運送費、保管料 Transportation and storage	1,770	1,900	129	107.3%
広告宣伝費 Advertising	1,316	706	△ 610	53.6%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	8,221	8,198	△ 22	99.7%
研究開発費 Research and development	792	792	△ 0	99.9%
管理費、その他 Other, net	5,523	6,214	690	112.5%
販売費及び一般管理費 SG&A expenses	17,624	17,811	186	101.1%
宝酒造 グループ Takara Shuzo Group	△ 134	830	964	—
タカラバイオ グループ Takara Bio Group	△ 358	65	424	—
宝ヘルスケア Takara Healthcare Inc.	△ 39	9	48	—
その他 Other, net	290	277	△ 12	95.6%
営業利益(△:損失) Operating income(Δ:loss)	△ 241	1,182	1,424	—
受取利息・配当金 Interest and Dividends income	218	267	48	122.3%
その他営業外収益 Other, net	182	203	21	111.8%
営業外収益 Non-operating income	400	470	70	117.5%
支払利息 Interest and discounts expenses	114	121	6	106.0%
その他営業外費用 Other, net	23	46	22	194.6%
営業外費用 Non-operating expenses	138	167	29	121.2%
経常利益(△:損失) Ordinary income(Δ:loss)	20	1,486	1,465	7228.5%
特別利益 Extraordinary gain	33	4	△ 28	15.1%
特別損失 Extraordinary loss	44	79	35	181.3%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	9	1,411	1,401	14778.5%
法人税、住民税及び事業税 Current income taxes	144	524	380	363.7%
法人税等調整額 Deferred income taxes				
少数株主損益調整前四半期純利益(△:損失) Income(Δ:loss) before minority interests	△ 134	886	1,021	—
少数株主利益(△:損失) Minority interests in net income(Δ:loss)	△ 47	75	122	—
四半期純利益(△:損失) Net income(Δ:loss)	△ 86	811	898	—
設備投資額(有形・無形) Capital expenditures	1,777	2,012	234	113.2%
減価償却費(有形・無形) Depreciation and Amortization	996	1,012	15	101.5%

営業外収益 Non-operating income	受取利息45、受取配当金221、持分法による投資利益102 など Interest income 45, Dividends income 221, Equity in earnings of affiliates 102, etc.
営業外費用 Non-operating expenses	支払利息49、社債利息71 など (前期:支払利息37、社債利息77 など) Interest expenses 49, Interest on bonds 71, etc. (FY2014(1Q): Interest expenses 37, Interest on bonds 77, etc.)
特別利益 Extraordinary gain	固定資産売却益4 など Gain on sales of noncurrent assets 4, etc.
特別損失 Extraordinary loss	固定資産除売却損37、役員退職慰労金34 など (前期:役員退職慰労金24 など) Loss on sales and retirement of noncurrent assets 37,Directors' retirement benefits 34, etc. (FY2014(1Q): Directors' retirement benefits 24, etc.)

2. 宝酒造グループ :Takara Shuzo Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成26年3月期 第1四半期	平成27年3月期 第1四半期 Apr. 1, 2014 - Jun. 30, 2014		
	実績(a) FY2014 (1stQ) Actual (a)	実績(b) FY2015 (1stQ) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	16,484	16,609	125	100.8%
清酒 Sake	3,910	4,238	327	108.4%
ソフトアルコール飲料 Light-alcohol refreshers	6,903	6,403	△ 500	92.8%
その他酒類 Other liquors	2,962	3,239	277	109.4%
本みりん Hon Mirin	3,330	3,097	△ 232	93.0%
その他調味料 Other seasonings	1,952	2,014	61	103.2%
原料用アルコール等 Raw alcohol	1,670	1,588	△ 81	95.1%
海外日本食材卸 Japanese food wholesale business in overseas markets	1,544	4,032	2,487	261.0%
その他 Other	3,219	3,146	△ 73	97.7%
売上高 Net sales	41,978	44,370	2,391	105.7%
売上原価 Cost of sales	27,242	28,623	1,380	105.1%
売上総利益 Gross profit	14,735	15,746	1,011	106.9%
運送費、保管料 Transportation and storage	1,623	1,726	103	106.4%
広告宣伝費 Advertising	1,182	599	△ 582	50.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	7,977	7,970	△ 7	99.9%
研究開発費 Research and development	85	84	△ 0	98.9%
管理費、その他 Other, net	4,000	4,534	534	113.3%
販売費及び一般管理費 SG&A expenses	14,869	14,916	46	100.3%
営業利益（△：損失） Operating income(Δ:loss)	△ 134	830	964	—
営業外収益 Non-operating income	149	193	44	130.0%
営業外費用 Non-operating expenses	45	92	46	202.3%
経常利益（△：損失） Ordinary income(Δ:loss)	△ 30	931	962	—
特別利益 Extraordinary gain	2	4	2	182.3%
特別損失 Extraordinary loss	30	67	37	221.1%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	△ 58	869	927	—
法人税、住民税及び事業税 Current income taxes	75	323	247	425.9%
法人税等調整額 Deferred income taxes				
少数株主損益調整前四半期純利益（△：損失） Income(Δ:loss) before minority interests	△ 134	545	680	—
少数株主利益（△：損失） Minority interests in net income(Δ:loss)	23	61	37	258.3%
四半期純利益（△：損失） Net income(Δ:loss)	△ 158	484	642	—
設備投資額（有形・無形） Capital expenditures	369	1,206	836	326.1%
減価償却費（有形・無形） Depreciation and Amortization	683	705	21	103.2%

*平成26年3月期の実績において、「その他」の一部を「その他酒類」と「海外日本食材卸」に組替えております。
（平成27年3月期の区分に合わせております。）

3. タカラバイオグループ :Takara Bio Group

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

	平成26年3月期 第1四半期	平成27年3月期 第1四半期 Apr. 1, 2014 - Jun. 30, 2014		
	実績(a) FY2014 (1stQ) Actual (a)	実績(b) FY2015 (1stQ) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	3,016	3,562	545	118.1%
理化学機器 Scientific instruments	266	293	26	109.9%
受託・その他ファイン Contracted service and other	492	487	△ 5	98.9%
バイオ産業支援　計 Bioindustry	3,776	4,342	566	115.0%
遺伝子医療 Gene therapy	—	—	—	—
医食品バイオ AgriBio	394	436	42	110.8%
売上高 Net sales	4,170	4,779	609	114.6%
売上原価 Cost of sales	1,977	2,024	47	102.4%
売上総利益 Gross profit	2,192	2,754	561	125.6%
運送費、保管料 Transportation and storage	121	146	24	120.2%
広告宣伝費 Advertising	44	28	△ 15	65.4%
販売促進費 Sales promotion	220	204	△ 16	92.5%
研究開発費 Research and development	704	703	△ 1	99.9%
管理費、その他 Other, net	1,459	1,605	146	110.0%
販売費及び一般管理費 SG&A expenses	2,551	2,689	137	105.4%
バイオ産業支援　計 Bioindustry	383	798	415	208.4%
遺伝子医療 Gene therapy	△ 215	△ 211	4	—
医食品バイオ AgriBio	△ 125	△ 149	△ 24	—
共通 Eliminations/Corporate	△ 401	△ 372	28	—
営業利益（△：損失） Operating income(Δ:loss)	△ 358	65	424	—
営業外収益 Non-operating income	69	55	△ 13	79.9%
営業外費用 Non-operating expenses	8	18	9	216.3%
経常利益（△：損失） Ordinary income(Δ:loss)	△ 297	102	400	—
特別利益 Extraordinary gain	0	—	△ 0	—
特別損失 Extraordinary loss	13	10	△ 2	82.3%
税金等調整前四半期純利益（△：損失） Income(Δ:loss) before income taxes	△ 310	91	402	—
法人税、住民税及び事業税 Current income taxes	△ 52	75	127	—
法人税等調整額 Deferred income taxes				
少数株主損益調整前四半期純利益（△：損失） Income(Δ:loss) before minority interests	△ 258	16	274	—
少数株主利益（△：損失） Minority interests in net income(Δ:loss)	△ 4	△ 2	1	—
四半期純利益（△：損失） Net income(Δ:loss)	△ 254	18	272	—

設備投資額（有形・無形） Capital expenditures	1,390	782	△ 608	56.3%
減価償却費（有形・無形） Depreciation and Amortization	271	269	△ 2	99.2%

4. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

		平成22年3月期 第1四半期 FY2010 (1stQ)	平成23年3月期 第1四半期 FY2011 (1stQ)	平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	前期対比 Change from FY2014(1stQ) 増減 Change	比 YOY%
売上高	Net sales	44,874	44,554	48,866	47,349	46,953	50,025	3,072	106.5%
売上原価	Cost of sales	27,928	27,234	30,007	29,075	29,570	31,031	1,461	104.9%
（売上高原価率）	(Ratio to Net sales)	62.2%	61.1%	61.4%	61.4%	63.0%	62.0%	-0.9pt	—
売上総利益	Gross profit	16,945	17,319	18,859	18,273	17,382	18,994	1,611	109.3%
販売費及び一般管理費	SG&A expenses	15,995	16,207	17,194	17,212	17,624	17,811	186	101.1%
（売上高販管費率）	(Ratio to Net sales)	35.6%	36.4%	35.2%	36.4%	37.5%	35.6%	-1.9pt	—
営業利益（△：損失）	Operating income(Δ:loss)	950	1,111	1,664	1,061	△ 241	1,182	1,424	—
（売上高営業利益率）	(Ratio to Net Sales)	2.1%	2.5%	3.4%	2.2%	—	2.4%	—	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	7,285	7,590	7,909	8,170	8,221	8,198	△ 22	99.7%
（売上高販促費率）	(Ratio to Net sales)	16.2%	17.0%	16.2%	17.3%	17.5%	16.4%	-1.1pt	—
研究開発費	R&D expenses	840	685	701	737	792	792	△ 0	99.9%
（売上高研究開発費率）	(Ratio to Net sales)	1.9%	1.5%	1.4%	1.6%	1.7%	1.6%	-0.1pt	—
設備投資額（有形・無形）	Capital expenditures	774	532	638	998	1,777	2,012	234	113.2%
減価償却費（有形・無形）	Depreciation and Amortization	1,169	1,081	1,061	999	996	1,012	15	101.5%

宝酒造グループ :Takara Shuzo Group

（百万円 :Millions of Yen）

		平成22年3月期 第1四半期 FY2010 (1stQ)	平成23年3月期 第1四半期 FY2011 (1stQ)	平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	前期対比 Change from FY2014(1stQ) 増減 Change	比 YOY%
売上高	Net sales	39,959	39,728	44,118	42,291	41,978	44,370	2,391	105.7%
売上原価	Cost of sales	25,513	25,026	27,839	27,025	27,242	28,623	1,380	105.1%
（売上高原価率）	(Ratio to Net sales)	63.8%	63.0%	63.1%	63.9%	64.9%	64.5%	-0.4pt	—
売上総利益	Gross profit	14,446	14,702	16,278	15,266	14,735	15,746	1,011	106.9%
販売費及び一般管理費	SG&A expenses	13,474	13,727	14,781	14,680	14,869	14,916	46	100.3%
（売上高販管費率）	(Ratio to Net sales)	33.7%	34.6%	33.5%	34.7%	35.4%	33.6%	-1.8pt	—
営業利益（△：損失）	Operating income(Δ:loss)	971	974	1,496	585	△ 134	830	964	—
（売上高営業利益率）	(Ratio to Net sales)	2.4%	2.5%	3.4%	1.4%	—	1.9%	—	—
販売促進費、販売促進引当金繰入	Sales promotion and allowance for s.p.	7,010	7,356	7,694	7,942	7,977	7,970	△ 7	99.9%
（売上高販促費率）	(Ratio to Net sales)	17.5%	18.5%	17.4%	18.8%	19.0%	18.0%	-1.0pt	—
設備投資額（有形・無形）	Capital expenditures	537	265	386	331	369	1,206	836	326.1%
減価償却費（有形・無形）	Depreciation and Amortization	822	765	763	703	683	705	21	103.2%

タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

		平成22年3月期 第1四半期 FY2010 (1stQ)	平成23年3月期 第1四半期 FY2011 (1stQ)	平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	前期対比 Change from FY2014(1stQ) 増減 Change	比 YOY%
売上高	Net sales	3,852	3,772	3,823	4,104	4,170	4,779	609	114.6%
売上原価	Cost of sales	1,796	1,607	1,683	1,569	1,977	2,024	47	102.4%
（売上高原価率）	(Ratio to Net sales)	46.6%	42.6%	44.0%	38.2%	47.4%	42.4%	-5.1pt	—
売上総利益	Gross profit	2,056	2,164	2,140	2,535	2,192	2,754	561	125.6%
販売費及び一般管理費	SG&A expenses	2,305	2,197	2,188	2,360	2,551	2,689	137	105.4%
（売上高販管費率）	(Ratio to Net sales)	59.8%	58.3%	57.2%	57.5%	61.2%	56.3%	-4.9pt	—
営業利益（△：損失）	Operating income(Δ:loss)	△ 248	△ 32	△ 48	175	△ 358	65	424	—
（売上高営業利益率）	(Ratio to Net sales)	—	—	—	4.3%	—	1.4%	—	—
研究開発費	R&D expenses	751	595	608	646	704	703	△ 1	99.9%
（売上高研究開発費率）	(Ratio to Net sales)	19.5%	15.8%	15.9%	15.7%	16.9%	14.7%	-2.2pt	—
設備投資額（有形・無形）	Capital expenditures	231	227	238	475	1,390	782	△ 608	56.3%
減価償却費（有形・無形）	Depreciation and Amortization	312	280	263	263	271	269	△ 2	99.2%

宝ヘルスケア :Takara Healthcare Inc.

（百万円 :Millions of Yen）

		平成22年3月期 第1四半期 FY2010 (1stQ)	平成23年3月期 第1四半期 FY2011 (1stQ)	平成24年3月期 第1四半期 FY2012 (1stQ)	平成25年3月期 第1四半期 FY2013 (1stQ)	平成26年3月期 第1四半期 FY2014 (1stQ)	平成27年3月期 第1四半期 FY2015 (1stQ)	前期対比 Change from FY2014(1stQ) 増減 Change	比 YOY%
売上高	Net sales	733	693	615	551	292	385	92	131.6%
売上原価	Cost of sales	552	493	406	355	133	188	54	141.0%
（売上高原価率）	(Ratio to Net sales)	75.3%	71.1%	66.0%	64.5%	45.6%	48.8%	+3.3pt	—
売上総利益	Gross profit	180	200	209	195	159	197	37	123.7%
販売費及び一般管理費	SG&A expenses	243	272	252	203	198	188	△ 10	94.5%
（売上高販管費率）	(Ratio to Net sales)	33.2%	39.3%	41.1%	36.8%	67.9%	48.8%	-19.1pt	—
営業利益（△：損失）	Operating income(Δ:loss)	△ 62	△ 72	△ 43	△ 7	△ 39	9	48	—
（売上高営業利益率）	(Ratio to Net sales)	—	—	—	—	—	2.4%	—	—
ヘルスケア事業売上高	Net sales of Healthcare products	184	265	264	314	292	385	92	131.6%
設備投資額（有形・無形）	Capital expenditures	—	—	3	—	1	—	△ 1	—
減価償却費（有形・無形）	Depreciation and Amortization	2	2	2	2	0	0	0	1021.0%